UCB Secures FDA Approval for 320 mg Single-Injection Device of BIMZELX (bimekizumab-bkzx)
UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing…
Read More...
Read More...
